abstract |
A method of treating or preventing intraocular damage caused by reactive oxygen metabolites is provided. The method includes identifying a subject presenting the symptoms of pharmaceutically acceptable solution containing an effective concentration of a compound effective to reduce the amount of ROM in an individual. The compounds effective to reduce the amount of ROM in an individual include histamine and histamine related compounds. The specific disease states characterized by intraocular damage caused by reactive oxygen metabolites include proliferative diabetic retinopathy, preproliferative diabetic retinopathy, proliferative retinopathy, age-related macular degeneration, retinitis pigmentosa, and macular holes. A pharmaceutical composition including a pharmaceutically acceptable ophthalmic solution containing an effective concentration of a compound effective to reduce the amount of ROM in an individual is likewise provided. |